Introduction: Adjunctive therapy with polyclonal intravenous immunoglobins (IVIg) is currently used for preventing or managing infections and sepsis, especially in immunocompro-mised patients. The pathobiology of COVID-19 and the mechanisms of action of Ig led to the con-sideration of this adjunctive therapy, including in patients with respiratory failure due to the SARSCoV-2 infection. This manuscript reports the rationale, the available data and the results of a structured consensus on intravenous Ig therapy in patients with severe COVID-19. Methods: A panel of multidisciplinary experts defined the clinical phenotypes of COVID-19 patients with severe respiratory failure and, after literature review, voted for the agreement on the rationale and the potential role of IVIg therapy for each phenotype. Due to the scarce evidence available, a modified RAND/UCLA appropriateness method was used. Results: Three different phenotypes of COVID19 patients with severe respiratory failure were identified: patients with an abrupt and dysregulated hyperinflammatory response (early phase), patients with suspected immune paralysis (late phase) and patients with sepsis due to a hospital-acquired superinfection (sepsis by bacterial superinfec-tion). The rationale for intravenous Ig therapy in the early phase was considered uncertain whereas the panelists considered its use in the late phase and patients with sepsis/septic shock by bacterial superinfection appropriate. Conclusion: As with other immunotherapies, IVIg adjunctive therapy may have a potential role in the management of COVID-19 patients. The ongoing trials will clarify the appropriate target population and the true effectiveness.

Rationale for polyclonal intravenous immunoglobulin adjunctive therapy in covid-19 patients: Report of a structured multidisciplinary consensus / Coloretti, I.; Berlot, G.; Busani, S.; De Rosa, F. G.; Donati, A.; Forfori, F.; Grasselli, G.; Mirabella, L.; Tascini, C.; Viale, P.; Girardis, M.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:16(2021), pp. 3500-N/A. [10.3390/jcm10163500]

Rationale for polyclonal intravenous immunoglobulin adjunctive therapy in covid-19 patients: Report of a structured multidisciplinary consensus

Coloretti I.;Berlot G.;Busani S.;Grasselli G.;Girardis M.
2021

Abstract

Introduction: Adjunctive therapy with polyclonal intravenous immunoglobins (IVIg) is currently used for preventing or managing infections and sepsis, especially in immunocompro-mised patients. The pathobiology of COVID-19 and the mechanisms of action of Ig led to the con-sideration of this adjunctive therapy, including in patients with respiratory failure due to the SARSCoV-2 infection. This manuscript reports the rationale, the available data and the results of a structured consensus on intravenous Ig therapy in patients with severe COVID-19. Methods: A panel of multidisciplinary experts defined the clinical phenotypes of COVID-19 patients with severe respiratory failure and, after literature review, voted for the agreement on the rationale and the potential role of IVIg therapy for each phenotype. Due to the scarce evidence available, a modified RAND/UCLA appropriateness method was used. Results: Three different phenotypes of COVID19 patients with severe respiratory failure were identified: patients with an abrupt and dysregulated hyperinflammatory response (early phase), patients with suspected immune paralysis (late phase) and patients with sepsis due to a hospital-acquired superinfection (sepsis by bacterial superinfec-tion). The rationale for intravenous Ig therapy in the early phase was considered uncertain whereas the panelists considered its use in the late phase and patients with sepsis/septic shock by bacterial superinfection appropriate. Conclusion: As with other immunotherapies, IVIg adjunctive therapy may have a potential role in the management of COVID-19 patients. The ongoing trials will clarify the appropriate target population and the true effectiveness.
2021
10
16
3500
N/A
Rationale for polyclonal intravenous immunoglobulin adjunctive therapy in covid-19 patients: Report of a structured multidisciplinary consensus / Coloretti, I.; Berlot, G.; Busani, S.; De Rosa, F. G.; Donati, A.; Forfori, F.; Grasselli, G.; Mirabella, L.; Tascini, C.; Viale, P.; Girardis, M.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:16(2021), pp. 3500-N/A. [10.3390/jcm10163500]
Coloretti, I.; Berlot, G.; Busani, S.; De Rosa, F. G.; Donati, A.; Forfori, F.; Grasselli, G.; Mirabella, L.; Tascini, C.; Viale, P.; Girardis, M.
File in questo prodotto:
File Dimensione Formato  
jcm-10-03500-v2.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 802.41 kB
Formato Adobe PDF
802.41 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1280876
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact